Cómo citar
Resumen
Introducción: El cáncer de mama es la patología oncológica más frecuente en la población femenina a nivel mundial, se ha logrado determinar que su pronóstico está ligado al estadio tumoral diagnóstico, al tipo histológico y al tratamiento sistémico que se aplique según el subtipo molecular. El objetivo de este estudio es identificar la asociación de la expresión de los receptores hormonales, HER2/neu y el Ki67 con la sobrevida de los pacientes con cáncer de mama. Métodos: Se realizó un estudio descriptivo, retrospectivo en el Instituto Oncológico Nacional “Dr. Juan Tanca Marengo” en 284 pacientes con diagnóstico de cáncer de mama desde enero del 2006 hasta diciembre del 2013. Se analizaron variables de edad, diagnóstico histológico, estadio clínico, subtipos moleculares y sobrevida. Resultados: La edad media estaba comprendida entre 40 y 65 años, El diagnóstico histopatológico más frecuente fue el carcinoma ductal infiltrante en 236 pacientes, el porcentaje de Ki67 fue superior al 14% en el 60% de las fallecidas, el subtipo molecular más frecuente fue luminal B HER2 positivo con 95 casos y mayor mortalidad en los triples negativos con un 12.76%. Conclusión: El Ki67 es un marcador útil para valorar el pronóstico del paciente, la clasificación molecular del tumor permitirá dirigir el tratamiento específico y con ello obtener la reestadificación clínica del paciente.
Palabras clave
Citas
Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127(12), 2893-2917. https://doi.org/10.1002/ijc.25516
Cáncer en Guayaquil - Registro de Tumores 2011 - 2017 Autor: Sociedad de Lucha Contra el Cáncer Sede Nacional Instituto Oncológico Nacional - Dr. Juan Tanca Marengo Consejo Editorial: Dr. Juan Tanca Campozano Editor: Dr. Carlos Arreaga Salazar.
Morrow, M., Strom, E. A., Bassett, L. W., Dershaw, D. D., Fowble, B., Harris, J. R.& Winchester, D. P. (2002). Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA: A Cancer Journal for Clinicians, 52(5), 256-276. https://doi.org/10.3322/canjclin.52.5.256
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast.2008;17(4):323---34. https://doi.org/10.1016/j.breast.2008.02.002
McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067–9072. https://doi.org/10.1200/JCO.2004.01.0454
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820. https://doi.org/10.1056/NEJMoa053028
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672. https://doi.org/10.1056/NEJMoa052306
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684. https://doi.org/10.1056/NEJMoa052122
Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer. 2013;133(1):1---13. https://doi.org/10.1002/ijc.27997
Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-depen- dence of hazard ratios for prognostic factors inprimary breast can- cer. Breast Cancer Res Treat 1998;52:227–237. https://doi.org/10.1023/A:1006133418245
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0
Dowsett M, Allred C, Knox J, et al. Relationship between quanti- tative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex,Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059–1065. https://doi.org/10.1200/JCO.2007.12.9437
Viale G, Regan MM, Maiorano E, et al. Prognostic and predic- tive value of centrally reviewed expression of estrogen and pro- gesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvanttherapy for postmenopausal early breast can- cer: BIG 1-98. J Clin Oncol 2007;25:3846–3852. https://doi.org/10.1200/JCO.2007.11.9453
Viale G, Regan MM, Maiorano E, et al. Chemoendocrine com- pared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of es- trogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol 2008;26:1404–1410. https://doi.org/10.1200/JCO.2007.10.6393
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe- Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65. https://doi.org/10.1186/bcr2124
De Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504---13. https://doi.org/10.1038/sj.bjc.6603756
Sahin A, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma Significant correlation with prognosis. Cancer.1991;68(3):549---57. https://doi.org/10.1002/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J
Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104(11):1539---43. https://doi.org/10.1111/cas.12245
Park S, Koo JS., Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21(1): 50–7. https://doi.org/10.1016/j.breast.2011.07.008
JA VAN, CJH HAGE, VELDE JPJULIEN, Tubiana-Hulin M, Vandervelden C. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Impact of age, tumor characteristics, and treatment on local control and disease outcome in early stage breast cancer. 2001;: p. 33. https://doi.org/10.1200/JCO.2001.19.22.4224
Von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 2012; 30(15):1796-1804. https://doi.org/10.1200/JCO.2011.38.8595
Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G,et al. Prevalence, morphologic features and proliferation indices of breastcarcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-55.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep 1;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303
Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology. 2017; 35: p. 1061. https://doi.org/10.1200/JCO.2016.69.4406